Suneeta Pinnamaneni, MD
Medical Oncology · Leesburg, FLNPI 1265609580
Payments from drug & device makers
Across 207 payments — averaging $27.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Medtronic$989
- AstraZeneca$327
- Daiichi Sankyo Inc.$327
- Novartis$323
- Astellas Pharma US Inc$310
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,92287%
- Education$75113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 27 | $1,043 |
| Medtronic(2 entities) | 50 | $989 |
| AstraZeneca(2 entities) | 11 | $327 |
| Daiichi Sankyo Inc. | 15 | $327 |
| Novartis | 13 | $323 |
| Astellas Pharma US Inc | 7 | $310 |
| Regeneron Healthcare Solutions, Inc. | 11 | $302 |
| Biotronik NRO, Inc. | 4 | $270 |
| E.r. Squibb & Sons, L.L.C. | 15 | $215 |
| Merck | 9 | $209 |
| Johnson & Johnson | 6 | $192 |
| Sobi, Inc | 3 | $160 |
| Puma Biotechnology, Inc. | 3 | $157 |
| Abiomed | 1 | $135 |
| Pfizer | 5 | $96 |
| Nevro Corp. | 2 | $92 |
| Sanofi | 3 | $66 |
| Abbott | 3 | $59 |
| GSK | 3 | $59 |
| AbbVie | 2 | $58 |
| Amneal Pharmaceuticals LLC | 2 | $50 |
| Coherus Oncology, Inc. | 2 | $49 |
| Incyte Corporation | 1 | $29 |
| Genentech USA, Inc. | 1 | $27 |
| Caris MPI, Inc. | 1 | $19 |
| SPR Therapeutics, Inc | 1 | $18 |
| Partner Therapeutics, Inc. | 1 | $17 |
| Organon | 1 | $17 |
| Accord Healthcare, Inc. | 1 | $17 |
| CTI Biopharma Corp. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Array Biopharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,673 in reported general payments places this provider in the 25th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 64 | $1,018,594 |
| VerzenioAbemaciclib | 48 | $695,106 |
| KeytrudaPembrolizumab | 41 | $496,956 |
| ImbruvicaIbrutinib | 32 | $492,238 |
| SprycelDasatinib | 25 | $244,496 |
| TasignaNilotinib Hcl | 12 | $224,673 |
| DopteletAvatrombopag Maleate | 18 | $219,002 |
| ProcritEpoetin Alfa | 51 | $206,942 |
| XgevaDenosumab | 67 | $206,623 |
| CalquenceAcalabrutinib Maleate | 13 | $200,794 |
| AlimtaPemetrexed Disodium | 35 | $186,221 |
| PromactaEltrombopag Olamine | 13 | $169,601 |
| Lupron DepotLeuprolide Acetate | 27 | $157,234 |
| XtandiEnzalutamide | 11 | $152,860 |
| LibtayoCemiplimab-Rwlc | 15 | $144,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $29 | $1,018,59464 claims |
| Lilly USA, LLCVerzenio, Alimta | $1,043 | $881,32783 claims |
| MerckKeytruda | $209 | $496,95641 claims |
| NovartisTasigna, Promacta | $323 | $394,27425 claims |
| Johnson & JohnsonProcrit, Darzalex, Xarelto | $192 | $356,98276 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $215 | $244,49625 claims |
| AstraZenecaCalquence | $327 | $200,79413 claims |
| AbbVieLupron Depot | $58 | $157,23427 claims |
| Astellas Pharma US IncXtandi | $310 | $152,86011 claims |
| Regeneron Healthcare Solutions, Inc.Libtayo | $302 | $144,08015 claims |
| PfizerRuxience, Eliquis, Retacrit | $96 | $134,86779 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Leesburg
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
- Gail WrightHudson$13.8M
- Adil DaudTampa$13.3M
- Lowell HartFort Myers$10.1M
- Judy WangSarasota$9.8M
- Jonathan StrosbergTampa$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.